CD8A and neoplasm: High expression of Sb9 in tumor is negatively associated with prognosis and can be used to predict clinical outcome of ALK-negative anaplastic large cell lymphoma patients (127), hepatocellular carcinoma patients (117) and melanoma patients due to its negative correlation with CD8+ T cells (71, 94).